Zenobia partners with Alzheimer's Drug Discovery Foundation

Wednesday, August 15, 2012 11:54 AM

Zenobia Therapeutics, a fragment-based discovery company focused on central nervous system (CNS) disease based in San Diego, has formed a strategic partnership to provide Alzheimer's Drug Discovery Foundation (ADDF) researchers access to Zenobia's discovery platform.

Zenobia will provide ADDF researchers with complementary consultation to establish joint research plans that utilize the Zenobia platform and assist in preparation of grant proposals. Once funded, Zenobia will continue to work closely with researchers to evolve the plans as the program progresses. In addition, Zenobia will offer their premier Fragment Library 1 at a reduced price to ADDF researchers.

The Zenobia platform includes: a gene-to-structure platform with in-house cloning, expression and purification in E coli, insect and mammalian cells, a custom fragment library composed of diverse cores suitable for discovery of lead compounds that cross the blood-brain barrier, fragment screening by multiple validated methods and assay development (enzyme, cell and Drosophila). Zenobia will also provide access to their internal medicinal chemistry expertise to optimize the fragments to leads that are potent, selective and optimized for CNS ADME/PK properties.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs